Since the use of Src or ABCB1 inhibitors has shown modest results in the clinic due to their high toxicity [39,40], the targeting of SDCBP could be a more effective therapeutic strategy to eliminate resistant tumors in HNSCC patients effectively. This evidence concerns the gene SDCBP and head and neck squamous cell carcinoma.